INIBO-Injection to reduce fine lines and wrinkles

INIBO-Injection to reduce fine lines and wrinkles

INIBO, 100% purity of BoNT Type A Pharmaceutical has the best value in terms of its price and quality.


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
South Korea
Brand name
INIBO
Payment Terms
T/T
Production method
Available
Shipping / Lead Time
Negotiable / Negotiable
Keyword
filler, medical aesthetics, toxin
Category
Other Pharmaceuticals

Inibio co., ltd.

Membership
PRO
Country / Year Established
South Korea South Korea / 2017
Business type
Manufacturer
Verified Certificate

3

DUNS

GMP

Product name INIBO-Injection to reduce fine lines and wrinkles Certification -
Category Other Pharmaceuticals Material BONT
Keyword filler , medical aesthetics , toxin Unit Size 47.0 * 67.0 * 38.0 mm
Brand name INIBO Unit Weigh 60 g
origin South Korea Stock 50000
Supply type Available HS code 300290

Product Information

We are Inibio, a company established in 2017 that specializes in developing and manufacturing botulinum toxin products. 

We value advanced technology & challenge above all else and seek to continually grow & dynamically challenge new markets in the field of medical aesthetics.

 We are currently expanding our export efforts globally. We actively seek out opportunities to mutually grow business models together, and welcome collaborations. Feel free to contact us – we eagerly wait for your inquiries

 

Inibio was established in September 2017. though it has been only 5 years, we have done a lot of work and still go forward.

First is the cGMP-grade production facility. it is a 7th-floor building located nearby Seoul and the international airport enables us to export. We already got kGMP.

Moreover, from the beginning, we set our facility following the global standard for USA FDA & Europe EMA. It is thanks to our experts in each department such as manufacturing, R&D, QC..

They already have experienced the whole process such as development, and FDA approval. so we got it done quickly and can make the next step go fast.

In July 2023, we received approval for the kFDA. so we are concentrating on entering the global countries

l        cGMP grade production facilities->High quality.

l        Free Sales Certificate approved kFDA(Ministry of Food and Drug Safety)

l        Validation of strains by the world's leading authority->Original strain(No strain issue).

l        100% purity of 900kDA protein-> Fast on set time & Zero side effect in diffusion

l        Vacuum-drying method same as Allergan’s Product

l          Phase 1/2, 3 clinical trial in Korea completed

l          Completed NDA for kFDA -> Plan to launch in Korean Market end of 2023

Name of Drug: INIBO inj. 100 UNITS 

Pharmaceutical Dosage Form: Powder for solution for injection

Strength: 100 Units

Pack size    S: 47 x 38 x 67 mm, 1 vial/box

M: 199 x 99 x 73 mm, 10 ea/box

L: 515 x 415 x 165 mm, 200 ea/box

STORAGE: Unopened vials of INIBO inj. should be stored in a refrigerator 2° to 8°C (36º to 46ºF). Do not use after the expiration date on the vial.

B2B Trade

Price (FOB) Negotiable transportation Air Transportation
MOQ Negotiable Leadtime Negotiable
Payment Options T/T Shipping time Negotiable

Inibio co., ltd.

Country / Year Established
South Korea South Korea / 2017
Membership
PRO
Business type
Manufacturer

3

DUNS

GMP

President
KIM CHEONG SE
Address
2F Gonghangdaero 248, Gangseo-gu, Seoul, Korea
Product Category
Other Pharmaceuticals
Year Established
2017
No. of Total Employees
101-500
Company introduction

Inibio was established in September2017 to develop, manufacture, sell, and export biomedicine products. Our goalis to be a global expert providing total medical aesthetic solutions withproducts including botulinum toxins, hyaluronic acid fillers, and other DDSproducts.

During our first seed step, 3 years,we have done a lot of works to develop the main pipeline, botulinum toxin typeA, and continue to go on our journey.

We have cGMP grade productionfacility, which is designed to apply to International Standard, USA FDA, andEMA. Its annual production capacity is 2millions vials and it will be extendedto 6millions vials by 2022.

About approval, we have already got an export license (FSC)Currently, a patient injection was completed for the third phase clinical test.This is for 292 patients and it was 3 weeks ahead of the original schedule. So,we assure you that our first product, Inibo will be released in the second halfof next year in the Korean market.

Main Markets

China China

Main Product
Attached File

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat A new message arrives
from a business partner.

No Data

  • There is no data to load
  • Check out the My TK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more